Company: BSX
Filing Date: 2025-08-01
Form Type: 10-Q
Source: 0000885725-25-000041
Chunk: 143

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-08-01
Form: 10-Q
Item: Part I, Item 8
Chunk 143
---
 certain corporate-related expenses and certain transactions or adjustments that our CODM considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and European Union (EU) Medical Device Regulation (MDR) implementation costs. Although we exclude these amounts from segment expenses and segment operating income they are included in reported Income (loss) before income taxes within our accompanying unaudited consolidated statements of operations and are included in the reconciliation below. The CODM uses segment operating income in the budget and forecasting process and to monitor budget versus actual results, which are used in assessing the performance of the reportable segments and to allocate resources across our reportable segments Refer to Note K – Revenue for net sales by reportable segment presented in accordance with GAAP.A reconciliation of sales and operating income for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages). Prior period amounts have been restated at constant currency to conform to current year presentation. 

29

Three Months Ended June 30, 2025MedSurg% of net salesCardiovascular% of net salesTotalNet sales of reportable segments$1,714 $3,341 $5,055 Impact of foreign currency fluctuations6 Total net sales5,061 Segment expenses:Cost of products sold470 27.4 %1,046 31.3 %1,516 Selling, general and administrative expenses517 30.2 %908 27.2 %1,426 Research and development expenses120 7.0 %315 9.4 %435 Other segment items(1)8 0.5 %6 0.2 %14 Segment operating income(2)599 34.9 %1,065 31.9 %1,664 Unallocated amounts:Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(264)Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs(355)Amortization expense(225)Operating income (loss) 819 Other income (